Advisory Committee on Breast Cancer in Young Women (ACBCYW), 68782-68783 [2012-27901]
Download as PDF
<![CDATA[
68782
Federal Register / Vol. 77, No. 222 / Friday, November 16, 2012 / Notices
Dated:November 2, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity OSI),
Office of the Associate Director for Science
OADS), Office of the Director, Centers for
Disease Control and Prevention.
produce a set of sensitive indicators.
This surveillance will continue to
provide the evidence to enhance our
understanding of STDs, develop
intervention strategies, and evaluate the
impact of ongoing control efforts. CDC
works closely with state and local STD
control programs to monitor and
respond to STD outbreaks and trends in
STD-associated risk behavior. Users of
data include, but are not limited to,
congressional offices, state and local
health agencies, health care providers,
and other health-related groups.
CDC disseminates all STD
surveillance information through the
MMWR series of publications, including
the MMWR, the CDC Surveillance
Summaries, the Recommendations and
Reports, and the annual Summary of
Notifiable Diseases, United States.
Additionally, DSTDP publishes an
annual STD-specific surveillance
summary and supplements in hard copy
and on the Internet https://www.cdc.gov/
std/Stats/. CDC will use the findings
from this and other STD surveillance to
develop guidelines, control strategies,
and impact measures that monitor
trends in STDs in the United States. We
expect a total of 57 sites in state, city,
and territory health departments will be
submitting STD morbidity information
to CDC each week.
There is no cost to respondents other
than their time. The total estimated
annualized burden hours are 989.
Proposed Project
Nationally Notifiable Sexually
Transmitted Disease (STD) Morbidity
Surveillance (OMB No. 0920–0819,
Expiration 08/31/2012)—Reinstatement
with Change—National Center for HIV,
Viral Hepatitis, STD and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
[FR Doc. 2012–27835 Filed 11–15–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–13–0819]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Background and Brief Description
Because the STD epidemiology in the
United States is changing rapidly, CDC
must continue to monitor disease
indicators that are included in the STD
surveillance currently being
implemented. CDC is proposing to
continue electronic information
collection which includes information
elements that are integrated into the
existing nationally notifiable STDs.
These information elements are beyond
the scope of the OMB-approved
collection called Weekly and Annual
Morbidity and Mortality Reports
(MMWR, OMB #0920–0007). This
ongoing collection will have a title
change from ‘‘Sexually Transmitted
Disease (STD) Morbidity Surveillance’’
to ‘‘Nationally Notifiable Sexually
Transmitted Disease (STD) Morbidity
Surveillance and provides evidence to
better define STD distribution and
epidemiology in the United States. The
surveillance system modifies several
data elements currently included in the
MMWR collection and add others to
ESTIMATE OF ANNUALIZED BURDEN TABLE
Number of
respondents
Types of respondent
Form name
State Health Departments ..............................
Territorial Health Agencies .............................
City and county health departments ...............
Electronic STD Case report ...........................
Electronic STD Case report ...........................
Electronic STD Case report ...........................
Dated: November 2, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI),
Office of the Associate Director for Science
(OADS), Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2012–27832 Filed 11–15–12; 8:45 am]
mstockstill on DSK4VPTVN1PROD with NOTICES
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Breast Cancer
in Young Women (ACBCYW)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 9:30 a.m.–3:30 p.m. EST,
December 13, 2012.
Place: The meeting will be held via
teleconference.
VerDate Mar<15>2010
15:43 Nov 15, 2012
Jkt 229001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
50
5
2
Number of
responses per
respondent
52
52
52
Average
burden per
response
(in hours)
20/60
20/60
20/60
Teleconference login information is as
follows:
For Public:
TOLL-FREE PHONE #: 800–857–4875.
Participant passcode: 9377.
Net Conference URL: https://
www.mymeetings.com/nc/join/.
Conference number: PW6978681.
Audience passcode: 9377, or
Public can join the event directly:
https://www.mymeetings.com/nc/
join.php?i=PW6978681&p=9377&t=c.
There is also a toll number for anyone
outside of the USA:
TOLL # 1–212–287–1661.
Participant passcode: 9377.
Please go to the ACBCYW meeting Web
page to register for this meeting:
https://www.cdc.gov/cancer/breast/
what_cdc_is_doing/conference.htm.
E:\FR\FM\16NON1.SGM
16NON1
Federal Register / Vol. 77, No. 222 / Friday, November 16, 2012 / Notices
Status: Open to the public, limited only by
the number of phone lines available.
Purpose: The committee provides advice
and guidance to the Secretary, HHS; the
Assistant Secretary for Health; and the
Director, CDC, regarding the formative
research, development, implementation and
evaluation of evidence-based activities
designed to prevent breast cancer
(particularly among those at heightened risk)
and promote the early detection and support
of young women who develop the disease.
The advice provided by the Committee will
assist in ensuring scientific quality,
timeliness, utility, and dissemination of
credible appropriate messages and resource
materials.
Matters To Be Discussed: The agenda will
include discussions on approaches to
increase awareness of clinicians/practitioners
regarding topics such as breast health,
symptoms, diagnosis, and treatment of breast
cancer in young women; and information
needs and delivery mechanisms for women
at higher risks for developing breast cancer.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Temeika L. Fairley, Ph.D., Designated Federal
Officer, National Center for Chronic Disease
Prevention and Health Promotion, CDC, 5770
Buford Hwy, NE., Mailstop K52, Atlanta,
Georgia 30341, Telephone (770) 488–4518,
Fax (770) 488–4760, Email: acbcyw@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention, and Agency for Toxic Substances
and Disease Registry.
Dated: November 8, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–27901 Filed 11–15–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Prospective Grant of Co-Exclusive
License: Veterinary Vaccines for Rift
Valley Fever Virus
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
mstockstill on DSK4VPTVN1PROD with NOTICES
AGENCY:
This is a notice in accordance
with 35 U.S.C. 209(e) and 37 CFR
404.7(a)(1)(i) that the Technology
Transfer Office, Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS), is thinking about giving
SUMMARY:
VerDate Mar<15>2010
15:43 Nov 15, 2012
Jkt 229001
a co-exclusive license in Africa, in the
field of use of veterinary vaccines, to
practice the inventions listed in the
patent applications referred to below to
Deltamune Ltd., having a place of
business in Centurion, South Africa.
The patent rights in these inventions
have been assigned to the government of
the United States of America. The
patent applications(s) to be licensed are:
US Provisional Application 61/016,065,
filed 12/21/2007, entitled ‘‘Development of
Rift Valley Fever Virus Utilizing Reverse
Genetics,’’ US Provisional Application 61/
042,987, filed 4/7/2008, entitled
‘‘Recombinant Rift Valley Fever (RVF)
Viruses and Method of Use,’’ PCT
Application PCT/US2008/087023, filed 12/
16/2008, entitled ‘‘Recombinant Rift Valley
Fever (RVF) Viruses and Method of Use,’’ US
National Stage Application 12/809,561, filed
6/18/2010, entitled ‘‘Recombinant Rift Valley
Fever (RVF) Viruses and Methods of Use,’’
and all related continuing and foreign
patents/patent applications for the
technology family. CDC Technology ID No. I–
008–08.
Status: Pending.
Priority Date(s):
61/042,987: 4/7/2008
61/016,065: 12/21/2007
The planned co-exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7.
Technology: The technology allows
for the generation of precisely defined
attenuated vaccine constructs that
contain complete deletions of critical
virulence factors of Rift Valley Fever
(RVF) virus. These attenuated vaccines
constructs still have the ability to
induce robust protective immunity
following the administration of a single
vaccine dose in a rat model of lethal
disease. The vaccines can protect
immunized animals against virulent
virus challenge. The vaccine candidates
also allow for the differentiation of
naturally infected and vaccinated
animals—a feature that is critical in
agricultural settings. This approach will
allow for the rapid generation of
effective, safe RVF vaccine candidates to
control and prevent the spread of wildtype RVF virus in a variety of settings,
including preventing the infection of
humans or animals during endemic,
epidemic or epizootic situations in
affected countries, or for prophylactic
use among humans in high risk
occupational settings, or following
intentional release of RVF virus during
bioterrorism.
DATES: Only written comments and/or
applications for a license which are
received by CDC on or before December
17, 2012 will be considered.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
68783
Requests for a copy of these
patent applications, inquiries,
comments, and other materials relating
to the planned license should be
directed to Donald Prather, J.D., Ph.D.,
Technology Licensing and Marketing
Specialist, Technology Transfer Office,
Centers for Disease Control and
Prevention (CDC), 4770 Buford
Highway, Mailstop K–79, Atlanta, GA
30341, Telephone: (770) 488–8612;
Facsimile: (770) 488–8615; Email:
dmprather@cdc.gov.
SUPPLEMENTARY INFORMATION:
Applications for a license filed in
response to this notice will be treated as
objections to giving the planned license.
Comments and objections submitted
in response to this notice will not be
made available for public inspection,
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
ADDRESSES:
Dated: November 8, 2012.
J. Ronald Campbell,
Director, Division of Executive Secretariat,
Centers for Disease Control and Prevention.
[FR Doc. 2012–27896 Filed 11–15–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Prospective Grant of Exclusive
License: Veterinary Vaccines for Rift
Valley Fever Virus
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
This is a notice in accordance
with 35 U.S.C. 209(e) and 37 CFR
404.7(a)(1)(i) that the Technology
Transfer Office, Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS), is thinking of giving a
co-exclusive license in Africa, and an
exclusive license in all territories other
than Africa, in the field of use of
veterinary vaccines, to practice the
inventions listed in the patent
applications referred to below to Merial
Limited, having a place of business in
Duluth, Georgia. The patent rights in
these inventions have been assigned to
the government of the United States of
America. The patent application(s) to be
licensed are:
SUMMARY:
US Provisional Application 61/016,065,
filed 12/21/2007, entitled ‘‘Development of
Rift Valley Fever Virus Utilizing Reverse
Genetics,’’ US Provisional Application 61/
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 77, Number 222 (Friday, November 16, 2012)]
[Notices]
[Pages 68782-68783]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27901]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Breast Cancer in Young Women (ACBCYW)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Time and Date: 9:30 a.m.-3:30 p.m. EST, December 13, 2012.
Place: The meeting will be held via teleconference.
Teleconference login information is as follows:
For Public:
TOLL-FREE PHONE : 800-857-4875.
Participant passcode: 9377.
Net Conference URL: https://www.mymeetings.com/nc/join/.
Conference number: PW6978681.
Audience passcode: 9377, or
Public can join the event directly:
https://www.mymeetings.com/nc/join.php?i=PW6978681&p=9377&t=c.
There is also a toll number for anyone outside of the USA:
TOLL 1-212-287-1661.
Participant passcode: 9377.
Please go to the ACBCYW meeting Web page to register for this
meeting:
https://www.cdc.gov/cancer/breast/what_cdc_is_doing/conference.htm.
[[Page 68783]]
Status: Open to the public, limited only by the number of phone
lines available.
Purpose: The committee provides advice and guidance to the
Secretary, HHS; the Assistant Secretary for Health; and the
Director, CDC, regarding the formative research, development,
implementation and evaluation of evidence-based activities designed
to prevent breast cancer (particularly among those at heightened
risk) and promote the early detection and support of young women who
develop the disease. The advice provided by the Committee will
assist in ensuring scientific quality, timeliness, utility, and
dissemination of credible appropriate messages and resource
materials.
Matters To Be Discussed: The agenda will include discussions on
approaches to increase awareness of clinicians/practitioners
regarding topics such as breast health, symptoms, diagnosis, and
treatment of breast cancer in young women; and information needs and
delivery mechanisms for women at higher risks for developing breast
cancer.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Temeika L. Fairley, Ph.D.,
Designated Federal Officer, National Center for Chronic Disease
Prevention and Health Promotion, CDC, 5770 Buford Hwy, NE., Mailstop
K52, Atlanta, Georgia 30341, Telephone (770) 488-4518, Fax (770)
488-4760, Email: acbcyw@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention,
and Agency for Toxic Substances and Disease Registry.
Dated: November 8, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2012-27901 Filed 11-15-12; 8:45 am]
BILLING CODE 4163-18-P
